Open Access
- © Lisa M Kattenhorn
- , et al.
- 2022
Adeno-Associated Virus Gene Therapy for Liver Disease
- Lisa M Kattenhorn 1
- Christopher H Tipper 1
- Lorelei Stoica 1
- Deborah S Geraghty 1
- Teresa L Wright 1
- Reed Clark 1
- Samuel C Wadsworth 1
- 1 - na
Jun 28, 2022
Abstract
The field of adeno-associated virus (AAV) gene therapy has progressed rapidly over the past decade, with the advent of novel capsid serotype and organ-specific promoters, and an increasing understanding of the immune response to AAV administration. In particular, liver-directed therapy has made remarkable strides, with a number of clinical trials currently planned and ongoing in hemophilia A and B, as well as other liver disorders. This review focuses on liver-directed AAV gene therapy, including historic context, current challenges, and future developments.
Related Content
-
Primer
Orthogonal Validation in Genome Editing Discovery Work -
Primer
Solvent Precipitation Method Increases Protein Recovery for Proteomics -
Protocol
High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction -
Protocol
Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells -
Protocol
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene - More